CyGenica uses a non-viral, non-toxic platform to develop in vitro and in vivo delivery solutions for drugs, gene editing components, and antibiotics.
The most crucial issue of intracellular delivery for large molecules, especially for gene therapy, remains the cellular membrane. This biological barrier is a double-edged sword; while it prevents infectious agents from entering our body and causing disease, it also stands between the successful use of life-saving medicines and advanced therapeutic technologies.
The successful delivery of therapeutics into target cells and organelles would minimize the undesired ‘off target’ side effects and reduce the required dose.
Our founder’s father was diagnosed with cancer when she was still a student. She witnessed her father suffering from the side effects of his therapy over years. This life experience defined the goal of her life 'how to make cancer drugs safer and better' to make an impact in oncology and do her bit in the global fight against cancer.
CyGenica is the result of her and our team’s intense desire to make significant contributions to alleviate this suffering and improve the quality of life of millions of cancer patients.
"University College Cork (UCC) is Ireland's first five star university, ranks 2nd in Ireland in National ranking of Ireland's third level institutions and 32 in the world in Times Higher Education World Impact Ranking. Our collaboration with UCC started when we received an innovation voucher from Enterprise Ireland to work with Dr Florence McCarthy, Department of Chemistry & ABCRF for custom synthesis of modified antibiotics to support our work on antibiotic delivery. We continued our collaboration with Dr John V (Eoin) Fleming, Department of Biochemistry and Cell Biology by sponsoring a student (Ms Emer Cantillion) for her Masters followed by PhD program to support our work on novel protein chimera for the delivery of therapeutic proteins and nucleotides."
CyGenica’s CyVec platform is a proprietary engineered negatively charged molecule that works just like a molecular drill boring through the cell membrane to deliver molecular cargoes to the nucleus without causing any harm to the cell, solving the most crucial issue of targeted intracellular delivery. CyVec can be used to develop in vitro and in vivo delivery mechanisms for drugs, gene editing mechanisms and antibiotics.
Interested in collaborating with us? You can reach us on social media or through our contact form.